Trim21 depletion alleviates bone loss in osteoporosis via activation of YAP1/β-catenin signaling

Abstract

Despite the diverse roles of tripartite motif (Trim)-containing proteins in the regulation of autophagy, the innate immune response, and cell differentiation, their roles in skeletal diseases are largely unknown. We recently demonstrated that Trim21 plays a crucial role in regulating osteoblast (OB) differentiation in osteosarcoma. However, how Trim21 contributes to skeletal degenerative disorders, including osteoporosis, remains unknown. First, human and mouse bone specimens were evaluated, and the results showed that Trim21 expression was significantly elevated in bone tissues obtained from osteoporosis patients. Next, we found that global knockout of the Trim21 gene (KO, Trim21 ^−/−) resulted in higher bone mass compared to that of the control littermates. We further demonstrated that loss of Trim21 promoted bone formation by enhancing the osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) and elevating the activity of OBs; moreover, Trim21 depletion suppressed osteoclast (OC) formation of RAW264.7 cells. In addition, the differentiation of OCs from bone marrow-derived macrophages (BMMs) isolated from Trim21 ^−/− and Ctsk-cre; Trim21 ^f/f mice was largely compromised compared to that of the littermate control mice. Mechanistically, YAP1/β-catenin signaling was identified and demonstrated to be required for the Trim21-mediated osteogenic differentiation of BMSCs. More importantly, the loss of Trim21 prevented ovariectomy (OVX)- and lipopolysaccharide (LPS)-induced bone loss in vivo by orchestrating the coupling of OBs and OCs through YAP1 signaling. Our current study demonstrated that Trim21 is crucial for regulating OB-mediated bone formation and OC-mediated bone resorption, thereby providing a basis for exploring Trim21 as a novel dual-targeting approach for treating osteoporosis and pathological bone loss.

References

[1] Weivoda MM et al. Identification of osteoclast-osteoblast coupling factors in humans reveals links between bone and energy metabolism. Nat. Commun., 2020, 11

[2] Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet, 2011, 377: 1276-1287

[3] Gregson CL et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch. Osteoporos, 2022, 17

[4] Minisola S et al. Update on the safety and efficacy of teriparatide in the treatment of osteoporosis. Ther. Adv. Musculoskelet. Dis., 2019, 11: 1759720X19877994

[5] Langdahl BL. Overview of treatment approaches to osteoporosis. Br. J. Pharmacol., 2021, 178: 1891-1906

[6] Li H, Xiao Z, Quarles LD, Li W. Osteoporosis: mechanism, molecular target and current status on drug development. Curr. Med. Chem., 2021, 28: 1489-1507

[7] Langdahl B. Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches. Bone, 2020, 139: 115516

[8] Choi RB et al. Improving bone health by optimizing the anabolic action of Wnt inhibitor multitargeting. JBMR Plus, 2021, 5: e10462

[9] Tabacco G, Bilezikian JP. Osteoanabolic and dual action drugs. Br. J. Clin. Pharmacol., 2019, 85: 1084-1094

[10] Rauner M, Taipaleenmaki H, Tsourdi E, Winter EM. Osteoporosis treatment with anti-sclerostin antibodies-mechanisms of action and clinical application. J. Clin. Med., 2021, 10: 787

[11] Kimura T et al. TRIM-directed selective autophagy regulates immune activation. Autophagy, 2017, 13: 989-990

[12] Kimura T et al. TRIM-mediated precision autophagy targets cytoplasmic regulators of innate immunity. J. Cell Biol., 2015, 210: 973-989

[13] Kim K, Kim JH, Kim I, Seong S, Kim N. TRIM38 regulates NF-kappaB activation through TAB2 degradation in osteoclast and osteoblast differentiation. Bone, 2018, 113: 17-28

[14] Zhao Y et al. TRIM16 promotes osteogenic differentiation of human periodontal ligament stem cells by modulating CHIP-mediated degradation of RUNX2. Front. Cell Dev. Biol., 2020, 8: 625105

[15] Chen WT, Zhang F, Zhao XQ, Yu B, Wang BW. Galectin-3 and TRIM16 coregulate osteogenic differentiation of human bone marrow-derived mesenchymal stem cells at least partly via enhancing autophagy. Bone, 2019, 131: 115059

[16] Kunishita Y et al. TRIM21 dysfunction enhances aberrant B-cell differentiation in autoimmune pathogenesis. Front. Immunol., 2020, 11: 98

[17] Zhou T et al. Piezo1/2 mediate mechanotransduction essential for bone formation through concerted activation of NFAT-YAP1-ss-catenin. Elife, 2020, 9: e52779

[18] Zeng QZ et al. YWHAZ binds to TRIM21 but is not involved in TRIM21-stimulated osteosarcoma cell proliferation. Biomed. Environ. Sci., 2018, 31: 186-196

[19] Zhang HT et al. TRIM21-regulated Annexin A2 plasma membrane trafficking facilitates osteosarcoma cell differentiation through the TFEB-mediated autophagy. Cell Death Dis., 2021, 12

[20] Xian J, Liang D, Zhao C, Chen Y, Zhu Q. TRIM21 inhibits the osteogenic differentiation of mesenchymal stem cells by facilitating K48 ubiquitination-mediated degradation of Akt. Exp. Cell Res., 2022, 412: 113034

[21] Hou K et al. Loss of TRIM21 alleviates cardiotoxicity by suppressing ferroptosis induced by the chemotherapeutic agent doxorubicin. EBioMedicine, 2021, 69: 103456

[22] Zhou G et al. TRIM21 is decreased in colitis-associated cancer and negatively regulates epithelial carcinogenesis. Inflamm. Bowel Dis., 2021, 27: 458-468

[23] Sjostrand M et al. TRIM21 controls Toll-like receptor 2 responses in bone-marrow-derived macrophages. Immunology, 2020, 159: 335-343

[24] Pan JX et al. YAP promotes osteogenesis and suppresses adipogenic differentiation by regulating beta-catenin signaling. Bone Res., 2018, 6: 18

[25] Azzolin L et al. YAP/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. Cell, 2014, 158: 157-170

[26] Konsavage WM Jr., Yochum GS. Intersection of Hippo/YAP and Wnt/beta-catenin signaling pathways. Acta Biochim. Biophys. Sin. (Shanghai), 2013, 45: 71-79

[27] Takada K et al. Targeted disruption of the BCL9/beta-catenin complex inhibits oncogenic Wnt signaling. Sci. Transl. Med., 2012, 4: 148ra117

[28] Kodama Y, Hu CD. An improved bimolecular fluorescence complementation assay with a high signal-to-noise ratio. Biotechniques, 2010, 49: 793-805

[29] Foss S et al. TRIM21-from intracellular immunity to therapy. Front. Immunol., 2019, 10: 2049

[30] Yang L et al. Upregulated E3 ligase tripartite motif-containing protein 21 in psoriatic epidermis ubiquitylates nuclear factor-kappaB p65 subunit and promotes inflammation in keratinocytes. Br. J. Dermatol., 2021, 184: 111-122

[31] Clarke BL. Anti-sclerostin antibodies: utility in treatment of osteoporosis. Maturitas, 2014, 78: 199-204

[32] Zhen G et al. An antibody against Siglec-15 promotes bone formation and fracture healing by increasing TRAP(+) mononuclear cells and PDGF-BB secretion. Bone Res., 2021, 9: 47

[33] Guo J et al. TRIM33 is essential for osteoblast proliferation and differentiation via BMP pathway. J. Cell Physiol., 2017, 232: 3158-3169

[34] Chen Z et al. TRIM44 promotes quiescent multiple myeloma cell occupancy and survival in the osteoblastic niche via HIF-1alpha stabilization. Leukemia, 2019, 33: 469-486

[35] Si W, Zhou J, Zhao Y, Zheng J, Cui L. SET7/9 promotes multiple malignant processes in breast cancer development via RUNX2 activation and is negatively regulated by TRIM21. Cell Death Dis., 2020, 11

[36] Kiss L, James LC. The molecular mechanisms that drive intracellular neutralization by the antibody-receptor and RING E3 ligase TRIM21. Semin. Cell Dev. Biol., 2021, 26: 99-107

[37] Karasik D, Rivadeneira F, Johnson ML. The genetics of bone mass and susceptibility to bone diseases. Nat. Rev. Rheumatol., 2016, 12: 496

[38] Jia L et al. YAP balances the osteogenic and adipogenic differentiation of hPDLSCs in vitro partly through the Wnt/beta-catenin signaling pathway. Biochem. Biophys. Res. Commun., 2019, 518: 154-160

[39] Kegelman CD et al. YAP and TAZ mediate osteocyte perilacunar/canalicular remodeling. J. Bone Miner. Res., 2020, 35: 196-210

[40] Li Z et al. Role of TCF/LEF transcription factors in bone development and osteogenesis. Int. J. Med. Sci., 2018, 15: 1415-1422

[41] Son HS et al. Benzydamine inhibits osteoclast differentiation and bone resorption via down-regulation of interleukin-1 beta expression. Acta Pharm. Sin. B, 2020, 10: 462-474

[42] Liu T, Zhang L, Joo D, Sun SC. NF-kappaB signaling in inflammation. Signal Transduct. Target Ther., 2017, 2: 17023

[43] Wang H et al. LPLUNC1 stabilises PHB1 by counteracting TRIM21-mediated ubiquitination to inhibit NF-kappaB activity in nasopharyngeal carcinoma. Oncogene, 2019, 38: 5062-5075

[44] Zhang HT et al. The E3 ubiquitin ligase CHIP mediates ubiquitination and proteasomal degradation of PRMT5. Biochim. Biophys. Acta, 2016, 1863: 335-346

[45] Tang D et al. Cytoplasmic PCNA is located in the actin belt and involved in osteoclast differentiation. Aging (Albany NY), 2020, 12: 13297-13317

[46] Zhang HT et al. Sequential targeting of YAP1 and p21 enhances the elimination of senescent cells induced by the BET inhibitor JQ1. Cell Death Dis., 2021, 12

[47] Li YH et al. PRMT5-TRIM21 interaction regulates the senescence of osteosarcoma cells by targeting the TXNIP/p21 axis. Aging (Albany NY), 2020, 12: 2507-2529

[48] Wisniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nat. Methods, 2009, 6: 359-362

[49] Place DE et al. Osteoclast fusion and bone loss are restricted by interferon inducible guanylate binding proteins. Nat. Commun., 2021, 12

[50] Zou BH et al. Oridonin ameliorates inflammation-induced bone loss in mice via suppressing DC-STAMP expression. Acta Pharmacol. Sin., 2021, 42: 744-754

[51] Chen Y et al. GPR120 is an important inflammatory regulator in the development of osteoarthritis. Arthritis Res. Ther., 2018, 20: 163

Funding

National Natural Science Foundation of China (National Science Foundation of China)(81602360, 82072470, 82350003, 92049201)

Natural Science Foundation of Guangdong Province (Guangdong Natural Science Foundation)(2021A1515012154, 2019A1515011082, 2017A030313665, 2018A030313544, 2020B1515120038)

Guangzhou Municipal Science and Technology Project(201707010493, 202102010069)